Tonlamarsen clinical trials
Also written ION904.
How each study uses tonlamarsen is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tonlamarsen studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2021 (1)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Kardigan, Inc. (2) · Ionis Pharmaceuticals, Inc. (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test tonlamarsen.
Studies
Open first, then newest update. How each study uses tonlamarsen is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe HypertensionRecruitingPhase 2Kardigan, Inc.NCT07511361Written as Tonlamarsen
- A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)CompletedPhase 2Kardigan, Inc.NCT06864104Written as Tonlamarsen
- A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of ION904 in Participants With Uncontrolled HypertensionCompletedPhase 2Ionis Pharmaceuticals, Inc.NCT05314439Written as ION904
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION904CompletedPhase 1Ionis Pharmaceuticals, Inc.NCT04731623Written as ION904
Codes
What other systems call tonlamarsen · ClinicalTrials.gg INT018321
- UNII (FDA) W6YJ85G6YGTONLAMARSENOne source FDA
- NCI Thesaurus C188648TonlamarsenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | W6YJ85G6YG | TONLAMARSEN | One source FDA |
| NCI Thesaurus | C188648 | Tonlamarsen | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.